Electronic structures and SARs of the isomeric complexes α-, β-, γ-[Ru(mazpy)2Cl2] with different antitumor activities

被引:13
作者
Chen, JC [1 ]
Li, J [1 ]
Qian, L [1 ]
Zheng, KC [1 ]
机构
[1] Sun Yat Sen Univ, Sch Chem & Chem Engn, Guangzhou 510275, Peoples R China
来源
JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM | 2005年 / 728卷 / 1-3期
关键词
Ru(II) complex; phenylazopyrinedine; antitumor; density functional theory (DFT); structure-activity relationships (SARs);
D O I
10.1016/j.theochem.2005.05.005
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
Three recently found isomeric complexes alpha-, beta-, gamma-[Ru(mazpy)(2)Cl-2] 1-3 (mazpy=4-methyl-2-phenylazopyridine) with different antitumor activities have been computed using the DFT-B3LYP method. The electronic and geometric structures as well as the structure-activity relationships (SARs) of such a type of isomers were investigated. The results show that the differences of isomeric structures of these Ru(II) complexes have very important effects on their electronic structures and related properties. Some interesting electronic and geometric structural characteristics of these complexes have been revealed. First, the main-body (azopyridine) planes of two conjugative ligands (mazpy) in gamma-[Ru(mazpy)(2)Cl-2] 3 are almost located on the same plane, but those in alpha- or beta-[Ru(mazpy)(2)Cl-2] (1 or 2) are almost intervertical. Second, the energy order of the lowest unoccupied molecular orbitals (LUMOs) of the isomers is epsilon(L)(2) > epsilon(L)(1) > epsilon(L)(3), and the HOMOLUMO gap is Delta epsilon(L-H)(3) < Delta epsilon(L-H)(1) < Delta epsilon(L-H)(2). Third, the total dipole moments (mu) of the isomers are in the sequence of mu(2) > mu(1) > mu(3), while the order of the positive charges (Q(L)) in the ligand mazpy is Q(L)(3) > Q(L)(1) > Q(L)(2). These electronic and geometric structural characteristics can be used to reasonably explain the trend in the anticancer-activities (A) of these isomers, i.e. A(2) < A(1) < A(3). (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:93 / 101
页数:9
相关论文
共 53 条
[1]   Weighted HOMO-LUMO energy separation as an index of kinetic stability for fullerenes [J].
Aihara, J .
THEORETICAL CHEMISTRY ACCOUNTS, 1999, 102 (1-6) :134-138
[2]   In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer [J].
Aird, RE ;
Cummings, J ;
Ritchie, AA ;
Muir, M ;
Morris, RE ;
Chen, H ;
Sadler, PJ ;
Jodrell, DI .
BRITISH JOURNAL OF CANCER, 2002, 86 (10) :1652-1657
[3]  
[Anonymous], 1976, FRONTIER ORBITAL ORG
[4]   Synthesis, X-ray diffraction structures, spectroscopic properties, and in vitro antitumor activity of isomeric (1H-1,2+triazoIe)Ru(III) complexes [J].
Arion, VB ;
Reisner, E ;
Fremuth, M ;
Jakupec, MA ;
Keppler, BK ;
Kukushkin, VY ;
Pombeiro, AJL .
INORGANIC CHEMISTRY, 2003, 42 (19) :6024-6031
[5]   DENSITY-FUNCTIONAL THERMOCHEMISTRY .3. THE ROLE OF EXACT EXCHANGE [J].
BECKE, AD .
JOURNAL OF CHEMICAL PHYSICS, 1993, 98 (07) :5648-5652
[6]  
CARPENTER JE, 1988, J MOL STRUC-THEOCHEM, V46, P41, DOI 10.1016/0166-1280(88)80248-3
[7]   4-hydroxymethyl-3-aminoacridine derivatives as a new family of anticancer agents [J].
Charmantray, F ;
Demeunynck, M ;
Carrez, D ;
Croisy, A ;
Lansiaux, A ;
Bailly, C ;
Colson, P .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (06) :967-977
[8]   Non-platinum chemotherapeutic metallopharmaceuticals [J].
Clarke, MJ ;
Zhu, FC ;
Frasca, DR .
CHEMICAL REVIEWS, 1999, 99 (09) :2511-2533
[9]   Ruthenium metallopharmaceuticals (vol 232, pg 69, 2002) [J].
Clarke, MJ .
COORDINATION CHEMISTRY REVIEWS, 2003, 236 (1-2) :207-+
[10]   Ruthenium metallopharmaceuticals [J].
Clarke, MJ .
COORDINATION CHEMISTRY REVIEWS, 2002, 232 (1-2) :69-93